MediSieve through to final round in MassChallenge UK
MediSieve, the company behind the groundbreaking magnetic sieve that removes malaria-infected blood cells directly from patients' blood, has secured its place in the final round of MassChallenge UK.
MassChallenge is a global non-profit startup accelerator and competition for high-impact, early-stage entrepreneurs. It awards millions of pounds in no-equity, non-dilutive grants to startups showing the highest impact and potential during its eight-month process.
MediSieve is competing for shares of up to £500,000 in cash, which MassChallenge UK will award at the end of the programme in December 2016.
The development is the latest in a long series of successes for MediSieve, which in July became a finalist in the Best Start-up Medtech Company category in the OBN Awards.
Speaking at a reception for MassChallenge UK finalists,Dr George Frodsham, founder of MediSieve, said: "It's been an overwhelmingly exciting year for MediSieve. We've hit some big funding milestones that have enabled us to push forward with our product development, and won some prestige awards along the way. We're thrilled with the awareness that all this is raising for our device."
Dr Frodsham founded MediSieve in 2015. During the last 12 months, the company has:
secured £350,000 in seed funding from angel investors with expertise in the medical device and healthcare industries - they include leading patent attorneys, former CEOs and successful entrepreneurs in the field
received a Pathfinder Award from the Wellcome Trust - this provided MediSieve with £102,000 to fund a 12-month project to manufacture and test clinical prototypes of its device
won an Innovate UK Smart 2015/16 Proof of Concept Award grant worth £100,000
taken the runner-up spot at Pitch@Palace 5.0. Held at St. James's Palace, London, the event saw UK entrepreneurs pitch to around 300 CEOs, angel investors, mentors and key business partners
presented at the Royal Society of Medicine's 12th Medical Innovations Summit
been featured in The Telegraph and many other major journals and publications
MediSieve's treatment could be used when malaria drugs become ineffective or to supplement existing drug treatments. The magnetic device is aimed at the most vulnerable malaria patients - those whose cases are severe or drug-resistant. It could help patients recover faster, keep symptoms at bay and increase their likelihood of survival.
The MassChallenge UK Awards Ceremony will take place on 1 December 2016.
Watch Dr Frodham present MediSieve's pitch.
For more information, visitwww.medisieve.comand follow onTwitter.
Ends